Beam Therapeutics vs CropX
Side-by-side comparison of AI visibility scores, market position, and capabilities
Beam Therapeutics develops precision genetic medicines using base editing technology that makes single-letter DNA changes without cutting the double helix.
About
Beam Therapeutics is a genetic medicines company founded in 2017 by base editing pioneers David Liu, J. Keith Joung, and Feng Zhang, having raised over $600M and gone public on Nasdaq. The company is built around base editing, a technology that makes precise single nucleotide changes in DNA without creating double-strand breaks, reducing the risk of unintended insertions or deletions compared to traditional CRISPR. Beam is developing a portfolio of base editing medicines targeting blood disorders, liver diseases, and immuno-oncology, including sickle cell disease, beta-thalassemia, and various cancers. The company also employs prime editing, a newer and even more precise gene editing modality for more complex genetic changes. Beam's pipeline includes both in vivo therapies delivered directly into the body and ex vivo cell therapy approaches where patient cells are edited outside the body and reinfused. As a clinical-stage company, Beam has programs in IND-enabling and Phase 1 trials and represents one of the most advanced next-generation gene editing platforms in development.
$3.5M annual revenue 2025; $86.1M total funding (Series C Oct 2023); deployed in 60+ countries; acquired Regen adding 130K acres; 134 employees; precision agriculture market $8.7B 2024; subscription-based model
About
CropX was founded in 2014 in Tel Aviv, Israel, with the mission of helping farmers improve crop yields and reduce resource consumption through precision agriculture technology. The company developed soil sensing hardware and analytics software that translate subsurface soil data into actionable irrigation and nutrient management recommendations, enabling farms of any size to optimize inputs based on actual field conditions rather than generalized agronomic guidelines.\n\nCropX's platform combines wireless soil sensors that measure moisture, temperature, and electrical conductivity at multiple depths with a cloud-based analytics engine that integrates weather data, satellite imagery, and farm management records. Recommendations are delivered via a mobile app, enabling farm managers to make data-driven irrigation decisions in real time. The 2023 acquisition of Regen added 130,000 acres of managed farmland to its platform and expanded its capabilities in carbon and regenerative agriculture. CropX is deployed in 60+ countries across a diverse range of crops and farm types.\n\nCropX has raised $86.1M in total funding, including a Series C in October 2023, and has grown to serve 20,000+ customers with a team of 134 employees. The company's international deployment footprint — spanning North America, Europe, Australia, and emerging agricultural markets — reflects the universal applicability of data-driven soil management. CropX sits at the intersection of precision agriculture, water conservation, and sustainable farming, three of the highest-priority investment themes in global food systems.
AI Visibility Head-to-Head
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.